Evaxion biotech reports preclinical proof of concept data for evaxion's ai-powered vaccine platform raven for the design of a next generation sars-cov-2 vaccine

Copenhagen, denmark, june 03, 2021 (globe newswire) -- evaxion biotech a/s (nasdaq: evax), a clinical-stage biotech company developing ai-driven immunotherapies and vaccines to improve the lives of patients with cancer and infectious diseases, announced today new preclinical data from its adaptive and intelligent vaccine for a rapid response against corona viruses (aicov) program.
EVAX Ratings Summary
EVAX Quant Ranking